What does equitable global health research and delivery look like? Tackling Infections to Benefit Africa (TIBA) partnership as a case study.
Control strategies
Epidemiology
Health policy
Health services research
Health systems
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
21
10
2022
accepted:
24
01
2023
medline:
28
3
2023
entrez:
24
3
2023
pubmed:
25
3
2023
Statut:
ppublish
Résumé
There is a current global push to identify and implement best practice for delivering maximum impact from development research in low-income and middle-income countries. Here, we describe a model of research and capacity building that challenges traditional approaches taken by western funders in Africa. Tackling Infections to Benefit Africa (TIBA) is a global health research and delivery partnership with a focus on strengthening health systems to combat neglected tropical diseases, malaria and emerging pathogens in Africa. Partners are academic and research institutions based in Ghana, Sudan, Rwanda, Uganda, Kenya, Tanzania, Zimbabwe, Botswana, South Africa and the UK. Fifteen other African countries have participated in TIBA activities. With a starting budget of under £7 million, and in just 4 years, TIBA has had a verified impact on knowledge, policy practice and capacity building, and on national and international COVID-19 responses in multiple African countries. TIBA's impact is shown in context-specific metrics including: strengthening the evidence base underpinning international policy on neglected tropical diseases; 77% of research publications having Africa-based first and/or last authors; postgraduate, postdoctoral and professional training; career progression for African researchers and health professionals with no net brain drain from participating countries; and supporting African institutions. Training in real-time SARS-CoV-2 viral genome sequencing provided new national capabilities and capacities that contributed to both national responses and global health security through variant detection and tracking. TIBA's experience confirms that health research for Africa thrives when the agenda and priorities are set in Africa, by Africans, and the work is done in Africa. Here, we share 10 actionable recommendations for researchers and funders from our lessons learnt.
Identifiants
pubmed: 36963785
pii: bmjgh-2022-011028
doi: 10.1136/bmjgh-2022-011028
pmc: PMC10040064
pii:
doi:
Substances chimiques
2,3,5-triiodobenzoic acid
H575A4059Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
BMC Infect Dis. 2021 Feb 18;21(1):186
pubmed: 33602147
BMJ Glob Health. 2019 Oct 18;4(5):e001853
pubmed: 31750000
Nature. 2019 Nov;575(7784):567
pubmed: 31772371
BMJ Glob Health. 2023 Mar;8(3):
pubmed: 36963785
PLoS One. 2017 Oct 16;12(10):e0186237
pubmed: 29036174
BMJ Glob Health. 2019 Oct 18;4(5):e001855
pubmed: 31750001
Int J Equity Health. 2022 Aug 17;21(1):111
pubmed: 35978323
Lancet. 2008 Nov 1;372(9649):1590-3
pubmed: 18984193
PLoS Negl Trop Dis. 2021 Mar 31;15(3):e0009254
pubmed: 33788840
BMJ Glob Health. 2021 Jun;6(6):
pubmed: 34167963
Acta Trop. 2017 Nov;175:20-30
pubmed: 27005396
BMC Health Serv Res. 2017 Dec 4;17(Suppl 2):696
pubmed: 29219076
BMJ Glob Health. 2020 Jun;5(6):
pubmed: 32532759